Roche

CDSCO expert panel grants waiver for 920 mg Ocrelizumab, subject to Roche conducting a Phase 4 clinical trial in the Indian population for proposed indications

The Swiss pharma company has challenged a Delhi High Court ruling that allowed Natco Pharma to sell a generic version of its spinal muscular atrophy drug Risdiplam

'They (the next 125 years) look more challenging than the past 125 years. The world has changed. We have to make quicker decisions'

The company is booking a capital gain of about $14 billion on the investment at a time when the cost of acquisitions in pharma have been soaring

The Japanese conglomerate is now one of Roche's largest investors, according to data compiled by Bloomberg.

US health officials have granted emergency use for another antibody-drug to help hospitalised patients with the most dangerous cases of Covid-19.

Drug firm Roche India said it has received Emergency Use Authorisation from the Central Drugs Standards Control Organisation (CDSCO) for Roche's investigational antibody cocktail

Tocilizumab, sold under the brand name Actemra, is an intravenous anti-inflammatory monoclonal antibody drug used to treat rheumatoid arthritis

Roche is one of the main suppliers of diagnostic tests to Britain's National Health Service (NHS) Test and Trace programme

Roche has received authorisation from the United States' Food and Drug Administration (FDA) for its cobas 6800/8800 diagnostic tests for transplant patients

US company Blueprint, which has been working with Roche since 2016, could also receive up to $927 million in milestone payments, plus royalties on sales outside the United States

The deals cover Roche's arthritis drug RoActemra and Merck's multiple sclerosis drug Rebif - both seen as potential COVID-19 therapies

The Federal Trade Commission (FTC) and Britain's Competition and Markets Authority (CMA) approved the deal on Monday without demanding asset sales

The US Food and Drug Administration granted priority review for risdiplam, an oral medicine for those with the potentially deadly muscle-wasting disorder

Lung cancer is by far the biggest oncology market and first-line treatment provides access to the most patients

Biocon and Mylan told CCI that Roche misled doctors, regulators to thwart competition to Trastuzumab

Biocon and Mylan started marketing biosimilars of Roche's Trastuzumab drug in 2014

According to the annual report of Swiss drugmaker, it has around 91,000 employees in more than 100 countries

In India, Trastuzumab is sold by Roche under the brand names Herceptin, Herclon and Biceltis